Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Move Over Turing, Valeant – Mylan Next Target For Price Scrutiny

Executive Summary

So far, most of the attention on drug price increases has focused on Turing Pharmaceuticals AG and Valeant Pharmaceuticals International Inc. But Mylan NV soon could be in the bull's-eye of payers and lawmakers after hiking the prices of 24 of the firm's products by more than 20% in the past six month, with seven of those medicines' costs spiking more than 100%, Wells Fargo analyst David Maris said in a new report.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC065399

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel